Hangzhou Tigermed revises governance, reports H1 2025 financial results

Hangzhou Tigermed Consulting's Board of Directors and Supervisory Committee approved several key resolutions on August 28, 2025, including a comprehensive revision of the "Articles of Association" and updates to various internal governance policies. These revisions aim to strengthen regulatory compliance and operational efficiency, with some changes requiring shareholder approval. The company further clarified the roles of legal representatives, refined share class stipulations, and adjusted shareholder meeting procedures, while emphasizing responsibilities for directors and senior management regarding malfeasance.

The company's non-operating fund occupation and other related party fund transactions for the first half of 2025 include: Tigermed Co., Ltd. (Thailand) with a beginning balance of THB 149.92 and an ending balance of THB 163.60. PT Tigermed Medical Indonesia had a beginning balance of IDR 51.71 and an ending balance of IDR 38.84. Tigermed Vietnam Co., Limited had a beginning balance of VND 83.14 and an ending balance of VND 163.59.

The company's unaudited financial results for the first half of 2025 show total operating revenue of CNY 3.25 bn, a decrease of 3.21% from the previous year. Net profit attributable to shareholders decreased by 22.22% to CNY 383.34 m. Basic earnings per share were CNY 0.45. Operating cash flow improved significantly by 130.43% to CNY 408.62 m. The company has also completed the cancellation of 3,922,520 repurchased shares, reducing its total share capital.